Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for autoimmune hepatitis patients who fail standard treatment

NCT ID NCT03217422

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new biologic drug called VAY736 in 68 adults with autoimmune hepatitis who did not get better with or could not tolerate standard treatments. The goal was to see if VAY736 could safely help normalize liver enzyme levels. Participants received either VAY736 or a placebo, and those on placebo could later switch to the active drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

VAY736 (a biologic drug)

What this could lead to

If it works, VAY736 could offer a new treatment option for people with autoimmune hepatitis who don't respond to or can't tolerate standard therapies.

What could go wrong

This is an early-to-mid-stage trial with only 68 participants, so results may not apply to everyone. The drug may not improve liver health or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE HEPATITIS

Contacts and locations

Locations

  • Inland Empire Liver Foundation

    Rialto, California, 92377, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1056ABI, Argentina

  • Novartis Investigative Site

    CABA, C1181ACH, Argentina

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Edmonton, Alberta, T6G 2B7, Canada

  • Novartis Investigative Site

    Toronto, Ontario, M5G 2C4, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H2X 1R9, Canada

  • Novartis Investigative Site

    Prague, 12000, Czechia

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Aachen, 52074, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Hanover, 30625, Germany

  • Novartis Investigative Site

    Mainz, 55131, Germany

  • Novartis Investigative Site

    Sapporo, Hokkaido, 0068555, Japan

  • Novartis Investigative Site

    Takamatsu, Kagawa-ken, 760 8557, Japan

  • Novartis Investigative Site

    Itabashi Ku, Tokyo, 173 8606, Japan

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Madrid, 28046, Spain

  • Novartis Investigative Site

    Bern, 3010, Switzerland

  • Novartis Investigative Site

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Novartis Investigative Site

    London, SE5 9RS, United Kingdom

  • Novartis Investigative Site

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • Novartis Investigative Site

    Nottingham, NG7 2UH, United Kingdom

  • Novartis Investigative Site

    Oxford, OX3 9DU, United Kingdom

  • Southern California Research Center

    Coronado, California, 92118, United States

  • St. Lukes Advanced Liver Therapies

    Houston, Texas, 77030, United States

  • University of California Davis Medical Center

    Sacramento, California, 95817, United States